Merck terminates early the TRACER study of vorapaxar in Acute Coronary Syndrome

Merck Inc. has announced that the Phase III TRACER study of vorapaxar,a selective PAR-1 Thrombin Receptor Antagonist, was terminated early as the drug did not reduce the primary composite endpoints (CV Death, Myocardial Infarction, Stroke or Recurrent Ischaemia)and increased the risk of major bleeding, including intracranial haemorrhage. The secondary prevention trial called TRA-2P with vorapaxar in patients who had already experienced heart attack, stroke or peripheral arterial disease,continues.